{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '12.', 'INFORMED CONSENT, ETHICAL REVIEW, AND', 'REGULATORY CONSIDERATIONS', '12.1.', 'Informed Consent', 'The Investigator is responsible for identifying potential subjects from the SPIMM-300 study or', 'subjects that otherwise meets trial Inclusion/Exclusion Criteria. The Investigator is responsible', 'for ensuring that the subject understands the potential risks and benefits of participating in the', 'trial, including answering any questions the subject may have throughout the trial and sharing in', 'a timely manner any new information that may be relevant to the subject willingness to continue', 'his or her participation in the trial.', 'The ICF will be used to explain the potential risks and benefits of trial participation to the subject', 'in simple terms before the subject is entered into the trial, and to document that the subject is', 'satisfied with his or her understanding of the risks and benefits of participating in the trial and', 'desires to participate in the trial.', 'The Investigator is responsible for ensuring that informed consent is given by each subject or', 'legal representative. This includes obtaining the appropriate signatures and dates on the ICF prior', 'to the performance of any protocol procedures and prior to the administration of investigational', 'product.', 'As used in this protocol, the term \"informed consent\" includes all consent and assent given by', 'subject or their legal representatives.', '12.2.', 'Ethical Review', 'The Sponsor or its representatives must approve all ICFs before they are used at a clinical site.', 'All ICFs must be compliant with the ICH guideline on GCP.', 'Documentation of EC approval of the protocol and the ICFs must be provided to the Sponsor, or', 'designee before the trial may begin at the clinical site.', '12.3.', 'Regulatory Considerations', 'This trial will be conducted in accordance with:', '1. Consensus ethics principles derived from international ethics guidelines, including the', 'CIOMS International Ethical Guidelines', '1. The ICH GCP Guideline [E6]', '2. European Directive 2001/20/EC', '3. Applicable laws and regulations', 'The Investigator, Sponsor, or designee will promptly submit the protocol to applicable EC(s),', 'IRBs, Regulatory Authorities and other Regulatory bodies as required. Some of the obligations', 'of the Sponsor may be assigned to a third-party organization. Clinical sites will not commence', 'enrollment until Regulatory Authority submission/approval and site EC/IRB favorable', 'opinion/approval are granted.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '77']['SPIMM-301 Version 4.0', '15 June 2018', \"An identification code assigned to each subject will be used in lieu of the subject's name to\", \"protect the subject's identity when reporting AEs/ADEs and/or other trial-related data.\", '12.3.1.', 'Protocol Approval', \"The Sponsor's responsible medical officer will approve the protocol, confirming that, to the best\", 'of their knowledge, the protocol accurately describes the planned design and conduct of the trial.', '12.3.2.', 'Final Report Approval', \"The Sponsor's responsible medical officer will approve the final clinical trial report for this trial,\", 'confirming that, to the best of his or her knowledge, the report accurately describes the conduct', 'and results of the trial.', '12.3.3.', 'Trial Monitoring', 'The Investigators and institution(s) will permit trial-related monitoring of the eCRF data by', 'Stealth BioTherapeutics Inc., or their assignee by providing direct access to source data and/or', 'documents. The trial monitor will verify the eCRFs 100% against the source documentation.', 'Deviations from the protocol with regard to subject enrollment or trial conduct will be noted in a', 'database. Serious/major protocol deviations may be reported to EC(s), IRBs, Regulatory', 'Authorities and other Regulatory bodies as required. A Sponsor representative will visit the', 'clinical site to initiate the trial, prior to the first treatment of the first subject, and at agreed times', 'throughout the trial, including at the end of the trial. Drug dispensing and clinical drug supply', 'records will be 100% verified at the clinical site by the trial monitor. It is understood that all', 'subject specific information is confidential and no documentation that can link trial information', 'to the specific subject will be collected or retained by the Sponsor. Additional details will be', 'provided in a Clinical Monitoring Plan.', '12.3.4.', 'Retention of Records', 'All trial-related material including source documents, eCRFs, Central Authority, EC', 'correspondence, and analyses and any other documentation required by applicable laws and', 'regulations will be maintained for 15 years after completion of the trial or notification from the', 'Sponsor that the data can be destroyed, whichever comes first.', '12.3.5.', 'Disclosure of Information', 'Information concerning the investigational medication and patent application processes,', 'scientific data or other pertinent information is confidential and remains the property of Stealth', 'Bio Therapeutics Inc. The Investigator may use this information for the purposes of the trial only.', 'It is understood by the Investigator that Stealth Bio Therapeutics Inc., will use information', 'developed in this clinical trial in connection with the development of the investigational', 'medication and therefore may disclose it as required to other clinical Investigators and to', 'regulatory agencies. In order to allow the use of the information derived from this clinical trial,', 'the Investigator understands that he/she has an obligation to provide complete test results and all', 'data developed during this trial to the Sponsor.', 'The Investigator may not submit for publication or presentation the results of this trial without', 'first receiving written authorization from Stealth Bio Therapeutics Inc. Stealth Bio Therapeutics', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '78']\n\n###\n\n", "completion": "END"}